首页> 外文期刊>European journal of ophthalmology >Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy
【24h】

Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy

机译:玻璃体腔注射贝伐单抗治疗中心性浆液性脉络膜病变光动力治疗后的脉络膜新生血管形成

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose. To report the anatomic and functional outcome of intravitreal bevacizumab (IVB) to treat choroidal neovascularization (CNV) following photodynamic therapy (PDT) to treat recurrent central serous choroidopathy (CSC). Methods. This was an interventional case report in which verteporfin PDT was performed in a case of recurrent CSC. Results. Following PDT, the patient developed juxtafoveal CNV that was later treated by IVB, achieving CNV closure and recovery of visual acuity. Conclusions. Photodynamic therapy is a useful therapy to treat recurrent CSC, though it may be associated with potentially severe complications such as CNV. Intravitreal bevacizumab seems a good alternative treatment in the management of this condition.
机译:目的。报告玻璃体内贝伐单抗(IVB)在光动力疗法(PDT)治疗复发性中心性浆液性脉络膜疾病(CSC)后治疗脉络膜新生血管(CNV)的解剖学和功能结局。方法。这是一个介入性病例报告,其中在复发性CSC的情况下进行了维替泊芬PDT。结果。 PDT后,患者发展为近凹型CNV,随后通过IVB治疗,从而实现了CNV闭合和视力恢复。结论光动力疗法是治疗复发性CSC的有用疗法,尽管它可能与潜在的严重并发症如CNV有关。玻璃体内贝伐单抗似乎是治疗该病的一种很好的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号